Brain MRI Clinical Trial
— CALIOfficial title:
National, Multicentre, Prospective, Interventional Study of the Variability of Cerebral MRI Diffusion Parameters by Using a Patented Normalization Process Versus no Use of Normalization Process
| Verified date | July 2023 |
| Source | Braintale |
| Contact | URIET Dorothée |
| Phone | +33686116089 |
| dorothee.uriet[@]braintale.eu | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
BrainTale has developed a standardization approach based on averaging measurements in predefined brain regions of interest and use of reference data acquired from healthy volunteers under conditions (MRI machine, acquisition protocol) identical to those used for the examination of the patient. The present study is intended to support the normalization step on healthy volunteers in clinical centres that will be equipped with the BrainTale medical device software dedicated to clinical routine practice and to assess, through a multicentre study, the impact of this normalization step on the variability of the MRI diffusion parameters. The data collected will support characterization and modelisation of the variability to explore further biais corrections methods. The study will be conducted by neuroradiologists of the neuroradiology departments of five clinical centres in France.
| Status | Not yet recruiting |
| Enrollment | 60 |
| Est. completion date | May 2024 |
| Est. primary completion date | March 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: 1. Male or female aged 18 up to 80 years old 2. Covered by a healthcare insurance 3. Agreeing to be informed about any incidental finding discovered on brain MRI 4. Written informed consent form signed Exclusion Criteria: 1. History of brain pathology, cognitive or psychiatric disorder 2. Any contraindication * for undergoing brain MRI 3. Subject refusing to participate or having expressed refusal to data collection/processing or unable to give his/her agreement to participate 4. Vulnerable subject (i.e. pregnant or breast-feeding woman, child, subject under curatorship or deprived of liberty) - contraindications to MRI include: pacemaker, neural stimulator, intraocular or intracerebral device, cochlear implant, MR-incompatible prosthetic heart valves, any implant with metallic, ferromagnetic or electrically conductive parts, any metal in the body which cannot be removed, claustrophobia. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Braintale |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Intraclass Correlation Coefficient (ICC) | For assessment of the impact of calibration on test-retest repeatability of cerebral MRI diffusion parameters.
The Intraclass Correlation Coefficient (ICC) of cerebral MRI diffusion parameters (FA, MD, RD, AD) between the two measures made on the same patients, per center. |
Day 1 | |
| Other | percentage Coefficient of Variation (%CV) of the Neurite Orientation Dispersion and Density Imaging (NODDI) multishell diffusion scalar parameters. | For assessment of the variability of multishell diffusion parameters:
The percentage Coefficient of Variation (%CV) of the Neurite Orientation Dispersion and Density Imaging (NODDI) multishell diffusion scalar parameters, i.e. Neurite Density Index (NDI), Orientation Dispersion Index (ODI) and Free Water fraction (FW). |
Day 1 | |
| Other | percentage Coefficient of Variation (%CV) of the resting-state functional MRI (fMRI) parameters. | For assessment of the variability of resting state fMRI parameters:
The percentage Coefficient of Variation (%CV) of the resting-state functional MRI (fMRI) parameters: Regional Homogeneity (ReHo) and functional integration metrics. |
Day 1 | |
| Primary | Coefficients of Variation (%CV) of FA measurement | Percentage Coefficients of Variation (%CV) of FA measurements obtained from QC-passed DTI sequences before and after application of the normalization process. | Day 1 | |
| Secondary | Coefficients of Variation (%CV) of MD measurement | Percentage Coefficients of Variation (%CV) of MD measurements obtained from QC-passed DTI sequences before and after application of the normalization process. | Day 1 | |
| Secondary | Coefficients of Variation (%CV) of AD measurement | Percentage Coefficients of Variation (%CV) of AD measurements obtained from QC-passed DTI sequences before and after application of the normalization process. | Day 1 | |
| Secondary | Coefficients of Variation (%CV) of RD measurement | Percentage Coefficients of Variation (%CV) of RD measurements obtained from QC-passed DTI sequences before and after application of the normalization process. | Day 1 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01865357 -
Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI
|
N/A |